Evidence map›Paper›PMID 39130730›Full record

ArticleAccess microbiology2024

Investigating the effectiveness of commercially available mouthwash on SARS-CoV-2 in vivo using viable virus titre as the primary outcome. A randomised controlled trial.

D W Seymour, G Forshaw, M Porteous, D Mawer, F Wiggins, A Mitchell, C Hewitt, T Beetar-King, K A Davies, D Jackson and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Access microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

D W SeymourYork and Scarborough Teaching Hospitals NHS Foundation Trust, Wigginton Road, York, YO31 8HE, UK.
G ForshawYork and Scarborough Teaching Hospitals NHS Foundation Trust, Wigginton Road, York, YO31 8HE, UK.
M PorteousYork and Scarborough Teaching Hospitals NHS Foundation Trust, Wigginton Road, York, YO31 8HE, UK.
D MawerYork and Scarborough Teaching Hospitals NHS Foundation Trust, Wigginton Road, York, YO31 8HE, UK.
F WigginsYork Trials Unit, Department of Health Sciences, ARRC Building, University of York, Heslington, York, YO10 5DD, UK.
A MitchellYork Trials Unit, Department of Health Sciences, ARRC Building, University of York, Heslington, York, YO10 5DD, UK.
C HewittYork Trials Unit, Department of Health Sciences, ARRC Building, University of York, Heslington, York, YO10 5DD, UK.
T Beetar-KingHigh Containment Microbiology, United Kingdom Health Security Agency, 61 Colindale Avenue, Colindale, London, NW9 5EQ, UK.
K A DaviesHigh Containment Microbiology, United Kingdom Health Security Agency, 61 Colindale Avenue, Colindale, London, NW9 5EQ, UK.
D JacksonHigh Containment Microbiology, United Kingdom Health Security Agency, 61 Colindale Avenue, Colindale, London, NW9 5EQ, UK.
M J HannahHigh Containment Microbiology, United Kingdom Health Security Agency, 61 Colindale Avenue, Colindale, London, NW9 5EQ, UK.
M PitcherHigh Containment Microbiology, United Kingdom Health Security Agency, 61 Colindale Avenue, Colindale, London, NW9 5EQ, UK.
U ArnoldHigh Containment Microbiology, United Kingdom Health Security Agency, 61 Colindale Avenue, Colindale, London, NW9 5EQ, UK.
R StrachanHigh Containment Microbiology, United Kingdom Health Security Agency, 61 Colindale Avenue, Colindale, London, NW9 5EQ, UK.
M J KillipHigh Containment Microbiology, United Kingdom Health Security Agency, 61 Colindale Avenue, Colindale, London, NW9 5EQ, UK.
P J NixonYork and Scarborough Teaching Hospitals NHS Foundation Trust, Wigginton Road, York, YO31 8HE, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This multi-arm, parallel group, single-blinded randomised controlled trial aimed to assess three commercially available mouthwashes effectiveness against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This manuscript has been written in accordance with the CONSORT statement.

Indexed as

mouthwashsalivaSARS-CoV-2

Identifiers

PMID39130730
PMCPMC11316591

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.